Quarterly ResultMay 7, 2026, 05:22 PM
Immix Biopharma Q1 Net Loss Widens to $10.1M
AI Summary
Immix Biopharma reported a net loss of $10.1 million for the first quarter of 2026, significantly wider than the $4.5 million loss in Q1 2025, primarily due to increased research and development and general and administrative expenses. The company's cash, cash equivalents, and short-term investments stood at $90.6 million as of March 31, 2026, and it believes these funds are sufficient for at least the next 12 months. Immix Biopharma also increased its At The Market offering capacity to $100 million.
Key Highlights
- Net loss for Q1 2026 was $10.1 million, compared to $4.5 million in Q1 2025.
- Total operating expenses increased to $10.8 million in Q1 2026 from $4.7 million in Q1 2025.
- Research and development expenses rose to $6.0 million in Q1 2026 from $2.0 million in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $90.6 million as of March 31, 2026.
- Net cash used in operating activities was $9.8 million in Q1 2026, up from $1.7 million in Q1 2025.
- Amended At The Market (ATM) offering capacity increased to $100 million on March 25, 2026.
- Received $1.5 million in grant reimbursements in Q1 2026 from the $8.0 million CIRM grant.